COMPANY

Cerevance

Cerevance is focused on the development of cell-type specific treatments for neurodegenerative, psychiatric, and CNS-controlled metabolic disorders. From company website Source · Oct 12, 2026

Keywords: neurology Parkinson's disease psychiatry metabolic Parkinson Disease Safety Issues Tolerance CVN424 CVN766

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$20.0MRaised (2 yrs)2Trials (company is sponsor)

Timeline

May 12, 2026 Raise Private equity round — Series C: $20M (total, as published), announced May 12, 2026. Source: company release on GlobeNewswire. source ↗
Sep 20, 2024 Trial start Phase 3: To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications source ↗
Jan 17, 2022 Trial start 1: Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers source ↗

Funding

Raised: $20.0M. Last 2 years.

May 12, 2026 Private equity round — Series C: $20M (total, as published), announced May 12, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06553027	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	Phase 3	Active, not recruiting	Sep 20, 2024	2026-08 (estimated)
NCT05105243	Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers	1	Completed	Jan 17, 2022	Oct 30, 2022 (actual)